Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 164 for:    PEMT

Mucin in Sputum of CF During Pulmonary Exacerbation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00202072
Recruitment Status : Unknown
Verified September 2005 by Philipps University Marburg Medical Center.
Recruitment status was:  Recruiting
First Posted : September 20, 2005
Last Update Posted : September 20, 2005
Sponsor:
Information provided by:
Philipps University Marburg Medical Center

Brief Summary:
The purpose of this study is to determine whether mucin is increased during pulmonay exacerbations in adult patients with cystic fibrosis (CF).

Condition or disease
Cystic Fibrosis

Detailed Description:

CF is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study we found that mucins are decreased in the sputum of adult CF patients.

In this study we want to investigate the differences on the mucin and DNA quantity and quality of airway secretions in during pulmoanry exacerbation.We hypothesize that during an exacerbation the mucin and DNA amount is increasing.

The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-DNA-network) of the airway secretions in CF related to the severity of the disease.

We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis and dot-blot with specific antibodies we will analyze MUC5AC and MUC5B mucins. DNA amount will be measured by microfluorimetry. With the laser scanning confocal microscopy the mucin-DNA-network will be evaluated.

The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.


Layout table for study information
Study Type : Observational
Enrollment : 25 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Study Start Date : January 2004
Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cystic fibrosis
  • chronic pseudomonas aeruginosa inflammation
  • pulmonary exacerbation

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00202072


Contacts
Layout table for location contacts
Contact: Markus O Henke, MD 06421 ext 2866041 markus.henke@staff.uni-marburg.de

Locations
Layout table for location information
Germany
Pediatric department, CF center, University Giessen Recruiting
Giessen, Germany
Contact: Hermann Lindemann, MD    0641/99 ext 43430    Hermann.Lindemann@paediat.med.uni-giessen.de   
Pediatric department, CF center, University Marburg Recruiting
Marburg, Germany
Contact: Markus O Henke, MD    06421 ext 2866041    markus.henke@staff.uni-marburg.de   
Sponsors and Collaborators
Philipps University Marburg Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Markus O Henke, MD Philipps University Marburg Medical Center

Publications:
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00202072     History of Changes
Other Study ID Numbers: 208/03
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: September 20, 2005
Last Verified: September 2005

Keywords provided by Philipps University Marburg Medical Center:
lung
airway
pulmonary exacerbation
mucus

Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases